Cipla Ltd (CIPLA):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Cipla Ltd (CIPLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9882)・商品コード:DATA904C9882
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:91
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥79,500見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Cipla Ltd (Cipla) is a pharmaceutical company, which manufactures and distributes branded medicines, generics and active pharmaceutical ingredients (APIs). It offers products for the treatment of various conditions such as cardiovascular and pediatric diseases, dermatological and cosmetological conditions, HIV/AIDS, diabetes, hepatitis, infectious diseases and critical care, malaria, cancer, neurological, ophthalmic, respiratory and urological conditions, osteoporosis and women’s health. The company also operates in consumer healthcare and biosimilar businesses. Cipla also manufactures metered-dose inhaler devices, spacers and related devices; and conducts R&D to develop new medicines and drug delivery systems. The company has operations in India, North America, South Africa and major regulated and emerging markets. Cipla is headquartered in Mumbai, Maharashtra, India.

Cipla Ltd (CIPLA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cipla Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Cipla Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Cipla Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17
Cipla Acquires Product Line from Camber Pharma 18
Cipla Acquires Marketing Rights for Skin Care Products from Percos India 19
Cipla to Acquire Manufacturing Facility in Goa from Okasa for USD4.8 Million 20
Cipla to Acquire Manufacturing Facility in Maharashtra from Okasa Pharma for USD12 Million 21
Private Equity 22
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 22
FIL Capital to Invest in Cipla Health 24
Partnerships 25
Cipla Enters into Marketing Partnership with Eli Lilly & Company (India) 25
MannKind to Enter into Marketing and Distribution Agreement with Cipla 26
Cipla and Roche Products Enter into Distribution Agreement 27
Cipla and Novartis May Enter into Co-Marketing Agreement 28
Cipla Enters into Distribution Agreement with BioQ Pharma 29
Cipla to Form Joint Venture with Biopharm 30
Cipla Enters into Distribution Agreement with Serum Institute 31
Cipla to Enter into Joint Venture Agreement with Cooper Pharma and PHI 32
Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab 33
Cipla Enters into Distribution Agreement with Serum Institute of India 34
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 35
Cipla Enters into Agreement with S&D Pharma 36
Cipla Enters into Co-Marketing Agreement with BioQuiddity for OneDose ReadyfusOR 37
Cipla Enters into Co-Marketing Agreement with Hetero Drugs 38
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 39
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 40
Licensing Agreements 41
Cipla Receives Rights from MSN Laboratories 41
Cipla Enters into Licensing Agreement with Stempeutics 42
Cipla USA Enters into Licensing Agreement with MEDRx for MRX-4TZT 43
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 44
Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 45
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 46
Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 47
Gilead Sciences Enters into Licensing Agreement with Cipla 48
Cipla Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 49
Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 50
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 51
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 52
Equity Offering 54
Cipla Quality Chemical Industries Raises USD41.8 Million in IPO of Shares 54
Cipla to Raise USD293.2 Million in Public Offering of Securities 55
Debt Offering 56
Cipla to Raise USD293.2 Million in Debt Offering 56
Acquisition 57
Cipla Medpro South Africa Acquires Mirren for USD33.2 Million 57
PharmaS to Acquire Cipla Croatia from Cipla Holding 58
Saba Investment to Sell 99% Stake in Al Jabal Drugs and Medical Appliances 59
Ascendis Health to Acquire 100% Stake in Cipla Agrimed Proprietary and Cipla Vet Proprietary 60
Allergan Acquires Chase Pharma 61
Cipla Acquires InvaGen Pharma and Exelan Pharma for USD550 Million 62
Cipla Divests 25% Stake in BioMab for USD25.8 Million 63
Cipla Acquires 51% Stake in Quality Chemicals for USD30 Million 64
Cipla to Acquire Duomed Produtos 65
Meditab to Sell 48.22% Stake in Jiangsu Cdymax for USD18.5 Million 66
Cipla Acquires Remaining 75% Stake in MabPharm 67
Cipla to Acquire 51% Stake in Yemen-Based Pharma Company for USD21 Million 68
Cipla (Mauritius) Acquires 60% Stake in Citihealth Imports for USD14 Million 69
Cipla Acquires Celeris, Medical Products Distributor 70
Cipla Acquires Additional 14.5% Stake In Quality Chemical Industries For US$15 Million 71
Cipla Completes Acquisition Of Cipla Medpro South Africa For US$512 Million 72
Cipla Sells Minority Stake In Desano, Maker Of Generic Products 74
Cipla Ltd – Key Competitors 75
Cipla Ltd – Key Employees 76
Cipla Ltd – Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Recent Developments 80
Strategy And Business Planning 80
Jul 13, 2018: Cipla Opens Up To Crowd Sourcing Innovation 80
Financial Announcements 82
Nov 07, 2017: Cipla Q2 FY18 Results Demonstrate Strong Growth Across Businesses and the Benefit of Operating Leverage 82
Aug 11, 2017: Cipla Announces Q1FY 18 Results 83
May 25, 2017: Cipla announces Q4 & FY 17 results Continued strong performance across key markets 84
Corporate Communications 85
Jan 09, 2017: Cipla appoints Peter Lankau as an Independent Director on its Board 85
Legal and Regulatory 86
Apr 16, 2018: Cipla: US FDA conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility 86
Government and Public Interest 87
Sep 10, 2018: Understanding depression and related symptoms key to suicide prevention in SA 87
Product News 88
Feb 17, 2017: Cipla launches Hepatitis B vaccine in India 88
Other Significant Developments 89
Jun 26, 2018: Consumers need to understand the risks associated with using medication to combat pain 89
Jun 12, 2018: Cipla Quality Chemical Industries: Building capacity to mitigate the burden of cancer in Uganda 90
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91

List of Tables
Cipla Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cipla Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cipla Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Cipla Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17
Cipla Acquires Product Line from Camber Pharma 18
Cipla Acquires Marketing Rights for Skin Care Products from Percos India 19
Cipla to Acquire Manufacturing Facility in Goa from Okasa for USD4.8 Million 20
Cipla to Acquire Manufacturing Facility in Maharashtra from Okasa Pharma for USD12 Million 21
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 22
FIL Capital to Invest in Cipla Health 24
Cipla Enters into Marketing Partnership with Eli Lilly & Company (India) 25
MannKind to Enter into Marketing and Distribution Agreement with Cipla 26
Cipla and Roche Products Enter into Distribution Agreement 27
Cipla and Novartis May Enter into Co-Marketing Agreement 28
Cipla Enters into Distribution Agreement with BioQ Pharma 29
Cipla to Form Joint Venture with Biopharm 30
Cipla Enters into Distribution Agreement with Serum Institute 31
Cipla to Enter into Joint Venture Agreement with Cooper Pharma and PHI 32
Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab 33
Cipla Enters into Distribution Agreement with Serum Institute of India 34
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 35
Cipla Enters into Agreement with S&D Pharma 36
Cipla Enters into Co-Marketing Agreement with BioQuiddity for OneDose ReadyfusOR 37
Cipla Enters into Co-Marketing Agreement with Hetero Drugs 38
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 39
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 40
Cipla Receives Rights from MSN Laboratories 41
Cipla Enters into Licensing Agreement with Stempeutics 42
Cipla USA Enters into Licensing Agreement with MEDRx for MRX-4TZT 43
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 44
Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 45
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 46
Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 47
Gilead Sciences Enters into Licensing Agreement with Cipla 48
Cipla Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 49
Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 50
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 51
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 52
Cipla Quality Chemical Industries Raises USD41.8 Million in IPO of Shares 54
Cipla to Raise USD293.2 Million in Public Offering of Securities 55
Cipla to Raise USD293.2 Million in Debt Offering 56
Cipla Medpro South Africa Acquires Mirren for USD33.2 Million 57
PharmaS to Acquire Cipla Croatia from Cipla Holding 58
Saba Investment to Sell 99% Stake in Al Jabal Drugs and Medical Appliances 59
Ascendis Health to Acquire 100% Stake in Cipla Agrimed Proprietary and Cipla Vet Proprietary 60
Allergan Acquires Chase Pharma 61
Cipla Acquires InvaGen Pharma and Exelan Pharma for USD550 Million 62
Cipla Divests 25% Stake in BioMab for USD25.8 Million 63
Cipla Acquires 51% Stake in Quality Chemicals for USD30 Million 64
Cipla to Acquire Duomed Produtos 65
Meditab to Sell 48.22% Stake in Jiangsu Cdymax for USD18.5 Million 66
Cipla Acquires Remaining 75% Stake in MabPharm 67
Cipla to Acquire 51% Stake in Yemen-Based Pharma Company for USD21 Million 68
Cipla (Mauritius) Acquires 60% Stake in Citihealth Imports for USD14 Million 69
Cipla Acquires Celeris, Medical Products Distributor 70
Cipla Acquires Additional 14.5% Stake In Quality Chemical Industries For US$15 Million 71
Cipla Completes Acquisition Of Cipla Medpro South Africa For US$512 Million 72
Cipla Sells Minority Stake In Desano, Maker Of Generic Products 74
Cipla Ltd, Key Competitors 75
Cipla Ltd, Key Employees 76
Cipla Ltd, Subsidiaries 77

List of Figures
Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12

★調査レポート[Cipla Ltd (CIPLA):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9882)販売に関する免責事項を必ずご確認ください。
★調査レポート[Cipla Ltd (CIPLA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆